ATE472604T1 - Verfahren zur herstellung von proteinen - Google Patents

Verfahren zur herstellung von proteinen

Info

Publication number
ATE472604T1
ATE472604T1 AT03750495T AT03750495T ATE472604T1 AT E472604 T1 ATE472604 T1 AT E472604T1 AT 03750495 T AT03750495 T AT 03750495T AT 03750495 T AT03750495 T AT 03750495T AT E472604 T1 ATE472604 T1 AT E472604T1
Authority
AT
Austria
Prior art keywords
producing proteins
proteins
producing
transient expression
secreted protein
Prior art date
Application number
AT03750495T
Other languages
English (en)
Inventor
Gilbert Gorr
Heike Launhardt
Birgit Berg
Original Assignee
Greenovation Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20020020382 external-priority patent/EP1398383A1/de
Application filed by Greenovation Biotech Gmbh filed Critical Greenovation Biotech Gmbh
Application granted granted Critical
Publication of ATE472604T1 publication Critical patent/ATE472604T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT03750495T 2002-09-12 2003-09-08 Verfahren zur herstellung von proteinen ATE472604T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20020020382 EP1398383A1 (de) 2002-09-12 2002-09-12 Verfahren zur Herstellung von Proteinen
EP03015881 2003-07-11
PCT/EP2003/009959 WO2004024927A1 (en) 2002-09-12 2003-09-08 Protein production method

Publications (1)

Publication Number Publication Date
ATE472604T1 true ATE472604T1 (de) 2010-07-15

Family

ID=31995519

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03750495T ATE472604T1 (de) 2002-09-12 2003-09-08 Verfahren zur herstellung von proteinen

Country Status (9)

Country Link
EP (1) EP1539966B1 (de)
AT (1) ATE472604T1 (de)
AU (1) AU2003270152A1 (de)
DE (1) DE60333201D1 (de)
DK (1) DK1539966T3 (de)
ES (1) ES2347325T3 (de)
PT (1) PT1539966E (de)
SI (1) SI1539966T1 (de)
WO (1) WO2004024927A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2341009T3 (es) 2003-11-05 2010-06-14 Roche Glycart Ag Anticuerpos cd20 con afinidad de union a receptores fc y funcion efectora.
WO2006082515A2 (en) 2005-02-07 2006-08-10 Glycart Biotechnology Ag Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
SG192479A1 (en) 2005-08-26 2013-08-30 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
SE529610C2 (sv) 2006-02-13 2007-10-02 Alfa Laval Corp Ab Centrifugalseparator
AR062223A1 (es) 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
SG178567A1 (en) 2009-08-31 2012-04-27 Roche Glycart Ag Affinity-matured humanized anti cea monoclonal antibodies
WO2011101328A2 (en) 2010-02-18 2011-08-25 Roche Glycart Ag Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
RU2584597C2 (ru) 2010-08-13 2016-05-20 Рош Гликарт Аг Антитела против а2 тенасцина с и способы их применения
MA34519B1 (fr) 2010-08-13 2013-09-02 Roche Glycart Ag Anticorps anti-fap et procédés d'utilisation
BR112013019083A2 (pt) 2011-02-10 2017-04-04 Roche Glycart Ag combinação de (a) um imunoconjugado, composição farmacêutica, uso de (a) um imunoconjugado, método de tratamento de uma doença em um individuo, método de estímulo de função celular efetora em um indivíduo e kit destinado ao tratamento de uma doença.
US20120213781A1 (en) 2011-02-11 2012-08-23 Zyngenia, Inc. Monovalent and Multivalent Multispecific Complexes and Uses Thereof
RS56793B1 (sr) 2011-03-02 2018-04-30 Roche Glycart Ag Cea antitela
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
AU2012258637B2 (en) 2011-05-24 2017-07-20 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
US9309306B2 (en) 2011-08-23 2016-04-12 Roche Glycart Ag Anti-MCSP antibodies
KR101721301B1 (ko) 2011-08-23 2017-03-29 로슈 글리카트 아게 이중특이적 항원 결합 분자
TR201816437T4 (tr) 2012-08-07 2018-11-21 Roche Glycart Ag Azalmış ve artmış efektör fonksiyonuna sahip olacak şekilde tasarlanmış iki antikor içeren bileşim.
WO2014131715A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Anti-mcsp antibodies
WO2016164308A1 (en) 2015-04-06 2016-10-13 Subdomain, Llc De novo binding domain containing polypeptides and uses thereof
EP3352791B1 (de) 2015-09-24 2019-10-30 AbVitro LLC Hiv-antikörperzusammensetzungen und verfahren zur verwendung
EP3178848A1 (de) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antikörper zur verringerung der bildung von antikörpern gegen medikamente
MX2018005229A (es) 2015-12-09 2019-04-29 F Hoffmann­La Roche Ag Anticuerpo anti-cd20 de tipo ii y usos del mismo.
JP2019517991A (ja) 2016-03-01 2019-06-27 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 低減したａｄｃｐを有するオビヌツズマブ及びリツキシマブ変異体
JP7089483B2 (ja) 2016-05-11 2022-06-22 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 修飾された抗テネイシン抗体及び使用方法
EP3252078A1 (de) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Typ ii anti-cd20 antikörper und anti-cd20/cd3 bispecific antikörper zur behandlung von krebs
EP3615572A1 (de) 2017-04-27 2020-03-04 Tesaro Inc. Gegen lymphozytenaktivierungsgen 3 (lag-3) gerichtete antikörpermittel und verwendungen davon
KR20200014304A (ko) 2017-06-02 2020-02-10 에프. 호프만-라 로슈 아게 암의 치료를 위한 제ii형 항-cd20 항체 및 항-cd20/항-cd3 이중특이적 항체
KR20200087176A (ko) 2017-11-14 2020-07-20 아르셀엑스, 인크. 다기능성 면역 세포 요법
WO2019099433A2 (en) 2017-11-14 2019-05-23 Arcellx, Inc. D-domain containing polypeptides and uses thereof
KR20210029158A (ko) 2018-06-03 2021-03-15 람카프 바이오 베타 엘티디. Ceacam5 및 cd47에 대한 이중특이성 항체
CN109295068B (zh) * 2018-09-14 2021-04-09 昆明理工大学 一种三七类甜蛋白基因PnTLP2及应用
CN109234284B (zh) * 2018-09-14 2021-04-09 昆明理工大学 一种三七类甜蛋白基因PnTLP5及应用
EP3831849A1 (de) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispezifische antikörper gegen ceacam5 und cd47
US20240026344A1 (en) 2020-10-13 2024-01-25 Avitide LLC Affinity ligand libraries of three-helix bundle proteins and uses thereof
US20230391829A1 (en) 2020-10-13 2023-12-07 Avitide LLC Aav8 affinity agents
EP4294542A1 (de) 2021-02-19 2023-12-27 Avitide LLC Aav2-affinitätswirkstoffe
JP2024514281A (ja) 2021-04-23 2024-04-01 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｎｋ細胞係合剤関連の有害作用の防止または軽減
WO2023122327A2 (en) 2021-12-24 2023-06-29 Avitide LLC Chi domain affinity ligands and agents
WO2024025911A1 (en) 2022-07-29 2024-02-01 Avitide LLC An affinity agent comprising a ligand that binds vce and comprises seq id no: 1
WO2024054656A2 (en) 2022-09-09 2024-03-14 Avitide LLC Affinity agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19947290A1 (de) * 1999-10-01 2001-04-19 Greenovation Pflanzenbiotechno Verfahren zur Herstellung proteinöser Substanzen

Also Published As

Publication number Publication date
AU2003270152A1 (en) 2004-04-30
DE60333201D1 (de) 2010-08-12
EP1539966A1 (de) 2005-06-15
SI1539966T1 (sl) 2010-10-29
DK1539966T3 (da) 2010-10-04
EP1539966B1 (de) 2010-06-30
PT1539966E (pt) 2010-09-14
WO2004024927A1 (en) 2004-03-25
ES2347325T3 (es) 2010-10-28

Similar Documents

Publication Publication Date Title
ATE472604T1 (de) Verfahren zur herstellung von proteinen
DE60335195D1 (de) Mutante e. coli-appa-phytaseenzyme und natürliche varianten davon, solche phytaseenzyme codierende nukleinsäuren, diese enthaltende vektoren und wirtszellen und verfahren zur herstellung und verwendung davon
ATE258189T1 (de) Verfahren zur herstellung von erythropoietin frei von tierischen proteinen
ATE380878T1 (de) Verfahren und zusammensetzungen für die proteinexpression und reinigung
DE602004008776D1 (de) Vorrichtung und verfahren zur konfiguration von sprachlesern unter verwendung semantischer analyse
SG149000A1 (en) Gag binding proteins
DE60125218D1 (de) Verfahren zur herstellung von humanem serumalbumin unter verwendung eines aufwarmschrittes
ATE520781T1 (de) Verfahren zur veränderung des gehalts von speicherstoffen in pflanzen
DE60036636D1 (de) Rinder-kollagen und verfahren zur herstelling rekombinantes gelatin
DE10390418D2 (de) Verfahren zur Herstellung von rekombinanten Proteinen in Mikroorganismen
ATE309353T1 (de) Verfahren zur herstellung von rekombinanten peptiden
ATE291936T1 (de) Kunsthaar und verfahren zur herstellung von haarersatz
GB0208041D0 (en) Method of culturing animal cells
DE60027932D1 (de) Verfahren zur herstellung von proteinhydrolysaten
ATE387497T1 (de) Samenspezifische 7s-alpha-promoter zur expression von genen in pflanzen
DE60120665D1 (de) Verfahren zur herstellung von geschnittenem tabak und herstellungssystem dafür
ATE499845T1 (de) Weisses proteinklebermehl und verfahren für seine verwendung
RS50075B (sr) Postupak za proizvodnju heterolognih proteinskih supstanci u biljnom materijalu
DE69630524D1 (de) Methoden zur aufreinigung von authentischem igf aus hefewirtszellen
ATE550437T1 (de) Verfahren zur expression und reinigung von immunotoxinen
DE60228588D1 (de) Verfahren zur konstruktion von künstlicher vegetation nach dem vorbild von natürlichem laub
ATE299944T1 (de) System zur herstellung von proteinen
ATE400662T1 (de) Herstellung von frostschutzprotein
ATE538209T1 (de) L-threonin herstellendes bakterium und verfahren zur herstellung von l-threonin
ATE269905T1 (de) Verfahren zur herstellung von proteinen in wirtszellen unter verwendung von chaperoninen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1539966

Country of ref document: EP